Fullerene-based Photosensitizers for PDT of Dysplastic Oral Keratinocytes

用于发育不良口腔角质形成细胞 PDT 的富勒烯光敏剂

• 批准号: 7216663
• 负责人: J TIM WHARTON
• 金额: $ 14.14万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-15 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7216663
• 关键词: Ablation; Actinic keratosis; Aftercare; Aminolevulinic Acid; Anthracenes; Area; Attention; Biodistribution; Biological; Carbon; Cells; Cicatrix; Class; Clinical; Color; Condition; Contracts; Cosmetics; Cryosurgery; Custom; Dental Education; Dentistry; Depth; Development; Diagnosis; Diagnostic; Disadvantaged; Disease; Disease Management; Disorder by Site; Doctor of Dental Surgery; Doctor of Philosophy; Dose; Drug Formulations; Early Diagnosis; Epithelial Cells; Epithelium; Esophageal; Evaluation; Excision; Eye; Face; Family suidae; Fullerenes; Future; Gel; Goals; Histocompatibility Testing; Histologic; Hour; In Vitro; Invasive; Lasers; Lesion; Light; Lighting; Malignant - descriptor; Malignant Neoplasms; Marketing; Medical; Mesocricetus auratus; Modeling; Modification; Mucous Membrane; Nature; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Oral; Oral cavity; Outcome; Outpatients; Oxygen; Package Insert; Patients; Penetration; Pharmaceutical Preparations; Pharyngeal structure; Phase; Phase II Clinical Trials; Photochemotherapy; Photosensitivity; Photosensitizing Agents; Phototoxicity; Physicians; Porphyrins; Premalignant; Procedures; Prodrugs; Rate; Reactive Oxygen Species; Recurrence; Science; Site; Skin; Source; Staging; Sunlight; Testing; Texture; Therapeutic Studies; Time; Tissues; Topical agent; Topical application; Toxic effect; Tumor Tissue; United States Food and Drug Administration; Visible Radiation; Visit; Water; Week; Work; Y base; absorption; anthracene; aqueous; base; cancer therapy; cancer type; college; design; experience; fullerene C60; functional disability; in vitro Model; in vivo; keratinocyte; killings; malignant mouth neoplasm; nanomaterials; novel; oral dysplasia; oral lesion; preclinical study; prevent; professor; protoporphyrin IX; tumor

DESCRIPTION (provided by applicant): We propose to develop new fullerene-based photosensitizers (PS) for topical photodynamic therapy of pre-malignant lesions of the oral cavity and pharynx. Photodynamic therapy (PDT) is a non-invasive procedure that uses a non-toxic photosensitizer and visible light to generate reactive oxygen species that kill biological cells. An advantage of PDT is its high level of selectivity, achieved through PS that selectively target specific cell or tissue types, the topical application of the PS to diseased tissue only, and the ability to control the illumination area. In addition, PDT can usually be performed on an out-patient basis. Currently, there are no photosensitizers approved for use with oral lesions. The potential advantages of our approach are: 1) Illumination can be carried out immediately after the topical application of the PS (there is no lengthy incubation period as required with other competing PS), 2) there is no need for laser light as with other PS, regular visible light is sufficient, 3) there is no skin and eye photosensitivity that many patients face after treatment. By developing a novel PS for the treatment of pre-malignant lesions, we will bring a welcome addition to the growing arsenal of cancer and pre-cancer treatments with superior ease of use, patient comfort, and cosmetic outcome.

描述(申请人提供)：我们建议开发基于富勒烯的新型光敏剂(PS)，用于口腔和咽部癌前病变的局部光动力治疗。光动力疗法(PDT)是一种非侵入性的治疗方法，它使用一种无毒的光敏剂和可见光来产生能杀死生物细胞的活性氧。光动力疗法的一个优点是其高水平的选择性，通过选择性地靶向特定细胞或组织类型的PS实现，仅将PS局部应用于病变组织，以及控制照明区域的能力。此外，PDT通常可以在门诊基础上进行。目前，还没有光敏剂被批准用于口腔损伤。我们方法的潜在优势是：1)局部应用PS后立即进行照射(没有其他竞争PS所要求的长潜伏期)，2)不需要像其他PS那样使用激光，常规可见光就足够了，3)许多患者在治疗后不会面临皮肤和眼睛的光敏问题。通过开发一种用于治疗癌前病变的新型PS，我们将以更好的易用性、患者舒适性和美容效果为不断增长的癌症和癌前治疗带来受欢迎的补充。